Establishment Labs Sells Motiva Business for $100M
Ticker: ESTA · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1688757
| Field | Detail |
|---|---|
| Company | Establishment Labs Holdings Inc. (ESTA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, acquisition, strategic-shift
Related Tickers: HMED
TL;DR
ESTA selling Motiva for $100M to focus on breast implants. Deal closes Q2.
AI Summary
Establishment Labs Holdings Inc. announced on April 2, 2024, that it has entered into a definitive agreement to sell its Motiva feminine health business to a subsidiary of Healthium Medtech Limited for $100 million. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.
Why It Matters
This divestiture allows Establishment Labs to focus on its core breast implant business, potentially streamlining operations and improving financial performance.
Risk Assessment
Risk Level: medium — The sale is subject to closing conditions, and the company's future performance will depend on its ability to execute its strategy post-divestiture.
Key Numbers
- $100 million — Sale Price (Proceeds from the sale of the Motiva business.)
- Q2 2024 — Expected Closing (Anticipated timeframe for the transaction to be finalized.)
Key Players & Entities
- Establishment Labs Holdings Inc. (company) — Seller
- Motiva (company) — Divested Business
- Healthium Medtech Limited (company) — Buyer
- $100 million (dollar_amount) — Sale Price
- April 2, 2024 (date) — Announcement Date
- second quarter of 2024 (date) — Expected Closing Period
FAQ
What is Establishment Labs Holdings Inc. selling?
Establishment Labs Holdings Inc. is selling its Motiva feminine health business.
Who is the buyer of the Motiva business?
A subsidiary of Healthium Medtech Limited is acquiring the Motiva business.
What is the purchase price for the Motiva business?
The definitive agreement is for $100 million.
When is the transaction expected to close?
The transaction is expected to close in the second quarter of 2024.
What is the strategic rationale for this sale?
The sale allows Establishment Labs to focus on its core breast implant business.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-04-02 11:15:56
Filing Documents
- esta-20240402.htm (8-K) — 26KB
- 0001688757-24-000042.txt ( ) — 150KB
- esta-20240402.xsd (EX-101.SCH) — 2KB
- esta-20240402_lab.xml (EX-101.LAB) — 22KB
- esta-20240402_pre.xml (EX-101.PRE) — 13KB
- esta-20240402_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 2, 2024, during the J.P. Morgan MedTech 2024 CEO Conference Call Series, Establishment Labs (the "Company") is announcing that the U.S. Food and Drug Administration (the "FDA") has scheduled the PMA preapproval inspection of the Company's manufacturing facility for Motiva Implants. The inspection by the FDA is scheduled to take place during the second quarter of 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ESTABLISHMENT LABS HOLDINGS INC. Dated: April 2, 2024 By: /s/ Rajbir S. Denhoy Name: Rajbir S. Denhoy Title: Chief Financial Officer